Skip to main content
TipRanks
Go Ultimate75% OFF

Lycopodium Limited (LW1) AI Stock Analysis

0 Followers
DE:LW1

Lycopodium Limited

(Frankfurt:LW1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Committed growth pipelineA substantial contracted base gives Lycopodium visibility into FY27 revenue and supports management’s ambitious growth outlook. The expanding study, project and managed-capex pipeline also creates opportunities to replenish committed work beyond the current forecast period.
Negative Factors
Recent profit moderationThe decline in net income from the prior peak indicates that earnings have not expanded as consistently as revenue. If this pattern persists, it could constrain margin progression and make the company more dependent on successful delivery of its planned growth pipeline.

Lycopodium Limited (LW1) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%DE:LW1+76.62%EWG+10.70%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 557.99M
Dividend Yield
3.31%
Average Volume (3M)
269
Price to Earnings (P/E)
19.8
Beta (1Y)
0.42
Revenue Growth
9.72%
EPS Growth
-7.72%
Country
Germany
Employees
1,300
Sector
Industrials
Sector Strength
63
Industry
Engineering & Construction

Lycopodium Limited Business Overview & Revenue Model

Company Description

Established in 1992 and based in East Perth, Australia, Lycopodium Limited provides expert engineering and complete project execution solutions across the natural resources, infrastructure, and industrial manufacturing sectors. The company operates t...

Lycopodium Limited Earnings Call Summary

Earnings Call Date:Aug 18, 2026(Q4-2026)|% Change Since:10.70%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call presents a strongly positive operational and financial picture: record revenue, solid margins hitting NPAT targets, robust cash and equity growth, and an expanding project and study pipeline with early and confident FY'27 guidance. Key achievements include numerous project awards, a growing Americas footprint and substantial increases in committed contracts and studies. Primary risks flagged are execution and sovereign risks in foreign jurisdictions, about 30% of FY'27 revenue still uncommitted, capacity constraints to meet demand (requiring further hiring and office expansion), and regional concentration (58% revenue from Africa). On balance, the highlights substantially outweigh the lowlights, though execution of the strong pipeline remains critical to realize guidance.

Positive Updates

Record Revenue and Strong Profitability
Revenue of $377.5M, up 11% year‑on‑year (record revenue). EBITDA of $59.5M (15.7% margin), Profit Before Tax $52.5M and NPAT $40.2M (10.6% NPAT margin), meeting the company's long‑term +10% NPAT target and at the top end of guidance. Earnings per share were $1.01.

Negative Updates

Sovereign and Execution Risks in Foreign Jurisdictions
A growing portion of the contract mix is in foreign jurisdictions, raising sovereign and execution risk. Management describes mitigation via split contracting and local entities and asserts they price for risk, but jurisdictional complexity remains an execution and risk factor.

Company Guidance

Lycopodium has brought forward FY‑27 guidance of AUD 540–580m revenue (midpoint AUD 560m, roughly +50% on FY‑26 revenue of $377.5m) and NPAT of $54–58m (consistent with its ~±10% NPAT margin target); management says just under 70% of FY‑27 revenue is already locked in (within ~AUD 661m of committed contracts), with >90 studies in the pipeline and six‑month momentum metrics including committed contracts +59%, revenue opportunity pipeline +8%, managed CapEx +32% and studies up twofold—backed by FY‑26 results of EBITDA $59.5m (15.7%), PBT $52.5m, NPAT $40.2m (10.6%), EPS $1.01, equity $170.7m (+13%), ROE 25%, cash $106.2m, NTA $3.92/share and minimal debt.

Lycopodium Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

DE:LW1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:MNDAU:MND80OutperformAUD 3.41B26.9322.77%3.18%29.43%50.05%
AU:NWHAU:NWH80OutperformAUD 3.09B19.9123.03%3.43%31.39%451.49%
AU:GNGAU:GNG74OutperformAUD 1.43B32.7453.12%3.46%2.95%12.85%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
AU:CVLAU:CVL60NeutralAUD 837.13M16.479.25%3.66%11.40%22.22%
AU:DOWAU:DOW59NeutralAUD 4.66B21.7911.01%4.02%-7.37%59.81%

* Industrials Sector Average

Performance Comparison

0%50%100%DE:LW1AU:DOWAU:MNDAU:NWHAU:GNGAU:CVLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:LW1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:LW1Lycopodium Limited12.305.3877.85%
AU:DOWDowner EDI Limited7.26-0.09-1.20%
AU:MNDMonadelphous Group Limited33.948.6434.13%
AU:NWHNRW Holdings Limited6.701.8939.21%
AU:GNGGR Engineering Services Ltd7.523.7599.36%
AU:CVLCivmec Singapore Limited Shs Chess Deposit Interests Repr 1 Sh1.640.3224.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.